HUE050706T2 - Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként - Google Patents

Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként

Info

Publication number: HUE050706T2
Authority: HU; Hungary
Prior art keywords: kinase inhibitors; compounds useful; indole carboxamides; carboxamides compounds; indole
Prior art date: 2014-10-24

Application number

HUE15790407A

Other languages

English (en)

Inventor

Saleem Ahmad

Joseph A Tino

John E Macor

Andrew J Tebben

Hua Gong

Qingjie Liu

Douglas G Batt

Khehyong Ngu

Scott Hunter Watterson

Weiwei Guo

Bertrand Myra Beaudoin

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-24

Filing date

2015-10-23

Publication date

2020-12-28

2015-10-23 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2020-12-28 Publication of HUE050706T2 publication Critical patent/HUE050706T2/hu

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems

HUE15790407A 2014-10-24 2015-10-23 Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként HUE050706T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462068225P	2014-10-24	2014-10-24

Publications (1)

Publication Number	Publication Date
HUE050706T2 true HUE050706T2 (hu)	2020-12-28

Family

ID=54427877

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE18205411A HUE050592T2 (hu)	2014-10-24	2015-10-23	Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként
HUE15790407A HUE050706T2 (hu)	2014-10-24	2015-10-23	Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HUE18205411A HUE050592T2 (hu)	2014-10-24	2015-10-23	Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként

Country Status (34)

Country	Link
US (8)	US9688629B2 (hu)
EP (2)	EP3209656B1 (hu)
JP (1)	JP6517928B2 (hu)
KR (2)	KR102030305B1 (hu)
CN (2)	CN107108583B (hu)
AR (2)	AR102426A1 (hu)
AU (2)	AU2015335694B2 (hu)
CA (1)	CA2965517C (hu)
CL (1)	CL2017000992A1 (hu)
CO (1)	CO2017004481A2 (hu)
CY (2)	CY1123401T1 (hu)
DK (2)	DK3209656T3 (hu)
EA (2)	EA032277B1 (hu)
ES (2)	ES2809974T3 (hu)
HR (2)	HRP20200819T1 (hu)
HU (2)	HUE050592T2 (hu)
IL (2)	IL251797B (hu)
LT (2)	LT3209656T (hu)
MA (2)	MA47043B1 (hu)
ME (2)	ME03807B (hu)
MX (2)	MX2017005259A (hu)
MY (2)	MY188048A (hu)
PE (2)	PE20190710A1 (hu)
PH (2)	PH12017500725B1 (hu)
PL (2)	PL3209656T3 (hu)
PT (2)	PT3461821T (hu)
RS (2)	RS60629B1 (hu)
SG (3)	SG10201903579SA (hu)
SI (2)	SI3461821T1 (hu)
TN (2)	TN2017000119A1 (hu)
TW (2)	TWI743401B (hu)
UY (1)	UY36371A (hu)
WO (1)	WO2016065226A1 (hu)
ZA (1)	ZA201804893B (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ712453A (en)	2013-03-15	2020-06-26	Incyte Holdings Corp	Tricyclic heterocycles as bet protein inhibitors
US10508259B2 (en)	2014-01-10	2019-12-17	Lost Spirits Technology Llc	Method for rapid maturation of distilled spirits using light, heat, and negative pressure processes
US10947488B2 (en)	2014-01-10	2021-03-16	Lost Spirits Technology Llc	Method for rapid maturation of distilled spirits using light and heat processes
SG11201608843TA (en)	2014-04-23	2016-11-29	Incyte Corp	1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
PT3209651T (pt)	2014-10-24	2019-12-30	Bristol Myers Squibb Co	Derivados de carbazol
EP3848353A1 (en)	2014-10-24	2021-07-14	Takeda Pharmaceutical Company Limited	Medicaments for the treatment of ophthalmic diseases
CA2965516A1 (en)	2014-10-24	2016-04-28	Bristol-Myers Squibb Company	Tricyclic atropisomer compounds
WO2017163078A1 (en)	2016-03-24	2017-09-28	Mission Therapeutics Limited	1-cyano-pyrrolidine derivatives as dbu inhibitors
KR102643344B1 (ko)	2016-06-20	2024-03-07	인사이트 코포레이션	Bet 저해제의 결정질 고체 형태
LT3507282T (lt) *	2016-09-02	2021-01-25	Bristol-Myers Squibb Company	Indolinių karboksamido junginių gamybos būdas
GB201616511D0 (en) *	2016-09-29	2016-11-16	Mission Therapeutics Limited	Novel compounds
GB201616627D0 (en) *	2016-09-30	2016-11-16	Mission Therapeutics Limited	Novel compounds
WO2018133139A1 (zh)	2017-01-21	2018-07-26	宁波知明生物科技有限公司	芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用
EP3694528A4 (en)	2017-10-13	2021-07-28	The Regents of the University of California	MTORC1 MODULATORS
IL300572A (en)	2018-02-13	2023-04-01	Gilead Sciences Inc	PD–1/PD–L1 inhibitors
WO2019208805A1 (ja)	2018-04-27	2019-10-31	小野薬品工業株式会社	Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
PT3820572T (pt) *	2018-07-13	2023-11-10	Gilead Sciences Inc	Inibidores pd-1/pd-l1
MA53388A (fr)	2018-07-25	2021-06-02	Novartis Ag	Inhibiteurs d'inflammasome nlrp3
KR102545594B1 (ko)	2018-07-31	2023-06-21	록쏘 온콜로지, 인코포레이티드	(s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
AR119731A1 (es)	2019-05-17	2022-01-05	Novartis Ag	Inhibidores del inflamasoma nlrp3
AU2020398840A1 (en) *	2019-12-04	2022-05-26	Aptinyx Inc.	Methods of treating cognitive impairment associated with neurodegenerative disease
CA3179637A1 (en) *	2020-06-02	2021-12-09	Craig Alan Coburn	Kinase inhibitors
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
US20230265083A1 (en) *	2020-08-10	2023-08-24	Prelude Therapeutics Incorporated	Heterocycle CDK Inhibitors And Their Use Thereof
MX2023001725A (es)	2020-08-14	2023-02-22	Novartis Ag	Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos.
WO2022089620A1 (zh) *	2020-10-30	2022-05-05	苏州晶云药物科技股份有限公司	吲哚基甲酰胺类化合物的新晶型及其制备方法
CN117015528A (zh) *	2021-01-12	2023-11-07	Gb005股份有限公司	作为激酶抑制剂的吲哚衍生物
CN114957241B (zh) *	2021-02-23	2023-08-22	药雅科技(上海)有限公司	杂环类化合物作为激酶抑制剂的制备及其应用
CN114853723B (zh) *	2021-02-03	2023-11-24	药雅科技(上海)有限公司	吲哚类化合物btk抑制剂的制备及其应用
CN115141176B (zh) *	2021-03-31	2023-08-22	药雅科技(上海)有限公司	炔代吲哚类fgfr抑制剂及其制备方法和用途
CN116348453A (zh) *	2021-04-25	2023-06-27	烨辉医药科技(上海)有限公司	杂芳族甲酰胺化合物及其用途
CN115368310A (zh)	2021-05-18	2022-11-22	奥库菲尔医药公司	合成甲磺酸酚妥拉明的方法
WO2023034732A1 (en)	2021-08-30	2023-03-09	Bristol-Myers Squibb Company	Compound useful for pet-imaging of bruton's tyrosine kinase
WO2023227080A1 (zh) *	2022-05-25	2023-11-30	百极弘烨(南通)医药科技有限公司	一种protac化合物、含其的药物组合物及其制备方法和应用
US20240067627A1 (en)	2022-08-03	2024-02-29	Novartis Ag	Nlrp3 inflammasome inhibitors
CN115010665A (zh) *	2022-08-05	2022-09-06	山东省食品药品检验研究院	一种硫酸特布他林杂质b的合成方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4200750A (en)	1977-01-07	1980-04-29	Westwood Pharmaceuticals Inc.	4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en)	1994-01-24	1995-07-25	Joseph A. Jakubowski	Beta-carboline thromboxane synthase inhibitors
WO2005014599A1 (en)	2003-06-04	2005-02-17	Cellular Genomics, Inc.	Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en)	2003-06-30	2008-07-01	Cgi Pharmaceuticals, Inc.	Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005047290A2 (en)	2003-11-11	2005-05-26	Cellular Genomics Inc.	Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
CN101060842A (zh) *	2004-09-21	2007-10-24	葛兰素集团有限公司	化合物
PE20060748A1 (es)	2004-09-21	2006-10-01	Smithkline Beecham Corp	Derivados de indolcarboxamida como inhibidores de quinasa ikk2
US7713973B2 (en)	2004-10-15	2010-05-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
JP2008519843A (ja)	2004-11-10	2008-06-12	シージーアイファーマスーティカルインコーポレーテッド	特定のイミダゾ［１，２−ａ］ビラジン−８−イラミンズ、その生成方法及びそれに関する使用方法
WO2006064355A2 (en)	2004-12-17	2006-06-22	Glenmark Pharmaceuticals S.A.	Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
KR101357524B1 (ko)	2005-03-10	2014-02-03	질레드 코네티컷 인코포레이티드	특정 치환된 아미드, 그의 제조 방법, 및 사용 방법
WO2006106326A1 (en)	2005-04-06	2006-10-12	Astrazeneca Ab	Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2007005534A2 (en) *	2005-06-30	2007-01-11	Smithkline Beecham Corporation	Chemical compounds
US8063071B2 (en)	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
US20070078136A1 (en)	2005-09-22	2007-04-05	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en)	2005-09-22	2010-05-25	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful as kinase modulators
US8518964B2 (en)	2005-11-22	2013-08-27	Merck Sharp & Dohme Corp.	Tricyclic compounds useful as inhibitors of kinases
TWI387585B (zh)	2006-09-01	2013-03-01	Dow Agrosciences Llc	殺蟲性之ｎ-取代（雜芳基）烷基烴基硫亞胺
EP2068849A2 (en)	2006-09-11	2009-06-17	CGI Pharmaceuticals, Inc.	Kinase inhibitors, and methods of using and identifying kinase inhibitors
RU2009113585A (ru)	2006-09-11	2010-10-20	Матрикс Лэборетериз Лтд. (In)	Производные дибензофурана в качестве ингибиторов pde-4 и pde-10
SI2530083T1 (sl)	2006-09-22	2016-09-30	Pharmacyclics Llc	Inhibitorji Bruton tirozin kinaze
CN101730699A (zh)	2007-03-21	2010-06-09	百时美施贵宝公司	可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
WO2008132500A2 (en)	2007-04-27	2008-11-06	Astrazeneca Ab	Chkl inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies
WO2008144253A1 (en) *	2007-05-14	2008-11-27	Irm Llc	Protein kinase inhibitors and methods for using thereof
US20090062251A1 (en)	2007-08-17	2009-03-05	Astrazeneca Ab	Novel Compounds 002
JP5489296B2 (ja)	2007-12-13	2014-05-14	メルク・シャープ・アンド・ドーム・コーポレーション	Ｊａｎｕｓキナーゼの阻害剤
PT2247558T (pt)	2008-02-14	2022-03-21	Lilly Co Eli	Novos agentes de imagiologia para deteção de disfunção neurológica
GB0809360D0 (en)	2008-05-22	2008-07-02	Isis Innovation	Calcium modulation
WO2010011837A1 (en)	2008-07-24	2010-01-28	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful as kinase modulators
EP2151441A1 (en)	2008-08-06	2010-02-10	Julius-Maximilians-Universität Würzburg	Beta-carbolin-derivates as substrates for an enzyme
MX2011006171A (es)	2008-12-19	2011-06-20	Squibb Bristol Myers Co	Compuestos de carbazol carboxamida utiles como inhibidores de cinasa.
CN101475571B (zh)	2009-01-21	2011-06-22	中国药科大学	β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
WO2010093949A2 (en)	2009-02-13	2010-08-19	Nextivity, Inc.	Remote control for booster
EP2440204B1 (en)	2009-06-12	2013-12-18	Bristol-Myers Squibb Company	Nicotinamide compounds useful as kinase modulators
US8846673B2 (en)	2009-08-11	2014-09-30	Bristol-Myers Squibb Company	Azaindazoles as kinase inhibitors and use thereof
UY33288A (es) *	2010-03-25	2011-10-31	Glaxosmithkline Llc	Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
WO2011159857A1 (en) *	2010-06-16	2011-12-22	Bristol-Myers Squibb Company	Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en)	2010-11-03	2012-05-23	Philip Morris Products S.A.	Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
RU2564445C2 (ru)	2010-11-15	2015-10-10	ВииВ Хелткер ЮКей Лимитед	Ингибиторы репликации вич
TW201247627A (en)	2011-04-28	2012-12-01	Bristol Myers Squibb Co	Novel bicyclic nitrogen containing heteroaryl TGR5 receptor modulators
JP5859640B2 (ja)	2011-05-17	2016-02-10	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ブルトンチロシンキナーゼ阻害剤
CA2841111A1 (en) *	2011-07-08	2013-01-17	Novartis Ag	Novel pyrrolo pyrimidine derivatives
CA2869954C (en) *	2012-04-20	2023-01-03	Advinus Therapeutics Limited	Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity
AR091273A1 (es) *	2012-06-08	2015-01-21	Biogen Idec Inc	Inhibidores de pirimidinil tirosina quinasa
CA2881351A1 (en) *	2012-09-07	2014-03-13	Novartis Ag	Indole carboxamide derivatives and uses thereof
TWI648272B (zh)	2013-06-25	2019-01-21	美商必治妥美雅史谷比公司	經取代之四氫咔唑及咔唑甲醯胺化合物
CN105473573B (zh)	2013-06-25	2018-03-16	百时美施贵宝公司	用作激酶抑制剂的咔唑甲酰胺化合物
UY35630A (es) *	2013-06-26	2015-01-30	Abbvie Inc	Carboxamidas primarias como inhibidores de btk

2015
- 2015-10-23 ME MEP-2020-158A patent/ME03807B/me unknown
- 2015-10-23 MA MA47043A patent/MA47043B1/fr unknown
- 2015-10-23 TN TN2017000119A patent/TN2017000119A1/en unknown
- 2015-10-23 SI SI201531306T patent/SI3461821T1/sl unknown
- 2015-10-23 KR KR1020187034789A patent/KR102030305B1/ko active IP Right Grant
- 2015-10-23 RS RS20200873A patent/RS60629B1/sr unknown
- 2015-10-23 ES ES18205411T patent/ES2809974T3/es active Active
- 2015-10-23 SG SG10201903579SA patent/SG10201903579SA/en unknown
- 2015-10-23 EA EA201790740A patent/EA032277B1/ru not_active IP Right Cessation
- 2015-10-23 DK DK15790407.9T patent/DK3209656T3/da active
- 2015-10-23 LT LTEP15790407.9T patent/LT3209656T/lt unknown
- 2015-10-23 AU AU2015335694A patent/AU2015335694B2/en active Active
- 2015-10-23 ES ES15790407T patent/ES2795366T3/es active Active
- 2015-10-23 HU HUE18205411A patent/HUE050592T2/hu unknown
- 2015-10-23 WO PCT/US2015/057055 patent/WO2016065226A1/en active Application Filing
- 2015-10-23 RS RS20200590A patent/RS60312B1/sr unknown
- 2015-10-23 MY MYPI2017701431A patent/MY188048A/en unknown
- 2015-10-23 US US14/921,347 patent/US9688629B2/en active Active
- 2015-10-23 PL PL15790407T patent/PL3209656T3/pl unknown
- 2015-10-23 EP EP15790407.9A patent/EP3209656B1/en active Active
- 2015-10-23 MX MX2017005259A patent/MX2017005259A/es unknown
- 2015-10-23 SG SG10201903578VA patent/SG10201903578VA/en unknown
- 2015-10-23 TN TNP/2018/000218A patent/TN2018000218A1/en unknown
- 2015-10-23 SG SG11201703188QA patent/SG11201703188QA/en unknown
- 2015-10-23 MX MX2020008024A patent/MX2020008024A/es unknown
- 2015-10-23 JP JP2017522111A patent/JP6517928B2/ja active Active
- 2015-10-23 LT LTEP18205411.4T patent/LT3461821T/lt unknown
- 2015-10-23 CN CN201580070681.1A patent/CN107108583B/zh active Active
- 2015-10-23 EP EP18205411.4A patent/EP3461821B1/en active Active
- 2015-10-23 PT PT182054114T patent/PT3461821T/pt unknown
- 2015-10-23 AR ARP150103454A patent/AR102426A1/es unknown
- 2015-10-23 CA CA2965517A patent/CA2965517C/en active Active
- 2015-10-23 MY MYPI2020006414A patent/MY195561A/en unknown
- 2015-10-23 TW TW107135190A patent/TWI743401B/zh active
- 2015-10-23 UY UY0001036371A patent/UY36371A/es unknown
- 2015-10-23 PE PE2019000250A patent/PE20190710A1/es unknown
- 2015-10-23 HU HUE15790407A patent/HUE050706T2/hu unknown
- 2015-10-23 SI SI201531216T patent/SI3209656T1/sl unknown
- 2015-10-23 PL PL18205411T patent/PL3461821T3/pl unknown
- 2015-10-23 CN CN201910717255.2A patent/CN110511209B/zh active Active
- 2015-10-23 PE PE2017000742A patent/PE20170695A1/es unknown
- 2015-10-23 DK DK18205411.4T patent/DK3461821T3/da active
- 2015-10-23 KR KR1020177013609A patent/KR102001745B1/ko active IP Right Grant
- 2015-10-23 EA EA201892207A patent/EA034931B1/ru not_active IP Right Cessation
- 2015-10-23 MA MA40301A patent/MA40301B1/fr unknown
- 2015-10-23 PT PT157904079T patent/PT3209656T/pt unknown
- 2015-10-23 TW TW104134977A patent/TWI744218B/zh active
2016
- 2016-11-17 US US15/354,613 patent/US9802915B2/en active Active
2017
- 2017-04-19 IL IL251797A patent/IL251797B/en active IP Right Grant
- 2017-04-20 PH PH12017500725A patent/PH12017500725B1/en unknown
- 2017-04-21 CL CL2017000992A patent/CL2017000992A1/es unknown
- 2017-05-03 CO CONC2017/0004481A patent/CO2017004481A2/es unknown
- 2017-05-30 US US15/608,340 patent/US9920031B2/en active Active
2018
- 2018-02-01 US US15/886,192 patent/US10329274B2/en active Active
- 2018-07-20 ZA ZA2018/04893A patent/ZA201804893B/en unknown
- 2018-10-08 IL IL262206A patent/IL262206B/en active IP Right Grant
2019
- 2019-04-29 US US16/396,879 patent/US10604504B2/en active Active
- 2019-12-19 AU AU2019283921A patent/AU2019283921B2/en active Active
2020
- 2020-01-28 US US16/774,202 patent/US20200165222A1/en not_active Abandoned
- 2020-02-05 PH PH12020500265A patent/PH12020500265A1/en unknown
- 2020-05-20 HR HRP20200819TT patent/HRP20200819T1/hr unknown
- 2020-06-30 CY CY20201100603T patent/CY1123401T1/el unknown
- 2020-07-22 HR HRP20201146TT patent/HRP20201146T1/hr unknown
- 2020-08-11 CY CY20201100747T patent/CY1123395T1/el unknown
- 2020-10-27 AR ARP200102971A patent/AR120317A2/es unknown
- 2020-12-03 US US17/110,643 patent/US11623921B2/en active Active
- 2020-12-17 ME MEP-2020-102A patent/ME03740B/me unknown
2023
- 2023-02-23 US US18/173,170 patent/US20230192645A1/en active Pending

Also Published As

Publication number	Publication date
US20210107891A1 (en)	2021-04-15
AU2015335694A1 (en)	2017-06-08
AR102426A1 (es)	2017-03-01
HUE050592T2 (hu)	2020-12-28
US9802915B2 (en)	2017-10-31
IL251797B (en)	2020-07-30
KR102001745B1 (ko)	2019-07-18
TWI743401B (zh)	2021-10-21
AU2015335694B2 (en)	2020-04-02
MA47043B1 (fr)	2021-09-30
CN107108583B (zh)	2020-11-13
EA201892207A1 (ru)	2019-02-28
US9688629B2 (en)	2017-06-27
MA47043A1 (fr)	2021-03-31
MX2017005259A (es)	2017-07-26
SG10201903579SA (en)	2019-05-30
WO2016065226A1 (en)	2016-04-28
EP3461821A1 (en)	2019-04-03
CL2017000992A1 (es)	2017-11-17
JP2017531679A (ja)	2017-10-26
EP3461821B1 (en)	2020-05-13
MX2020008024A (es)	2022-06-10
US10604504B2 (en)	2020-03-31
SI3461821T1 (sl)	2020-09-30
BR112017007956A2 (pt)	2017-12-19
TN2017000119A1 (en)	2018-07-04
MY195561A (en)	2023-02-02
CO2017004481A2 (es)	2017-08-10
ME03740B (me)	2021-01-20
CA2965517C (en)	2023-05-02
LT3209656T (lt)	2020-07-27
US20160115126A1 (en)	2016-04-28
CY1123395T1 (el)	2021-12-31
AU2019283921B2 (en)	2021-01-07
AR120317A2 (es)	2022-02-09
PL3209656T3 (pl)	2020-12-14
US20170066740A1 (en)	2017-03-09
TW201900612A (zh)	2019-01-01
UY36371A (es)	2016-04-29
CN110511209A (zh)	2019-11-29
MA40301A1 (fr)	2019-03-29
EA034931B1 (ru)	2020-04-08
LT3461821T (lt)	2020-08-10
US20170260160A1 (en)	2017-09-14
US20190248760A1 (en)	2019-08-15
HRP20200819T1 (hr)	2020-08-07
US9920031B2 (en)	2018-03-20
US20190119245A1 (en)	2019-04-25
AU2019283921A1 (en)	2020-01-16
RS60629B1 (sr)	2020-09-30
PT3209656T (pt)	2020-06-08
PE20170695A1 (es)	2017-05-26
HRP20201146T1 (hr)	2020-10-30
WO2016065226A8 (en)	2017-04-27
DK3209656T3 (da)	2020-07-13
TW201630880A (zh)	2016-09-01
CA2965517A1 (en)	2016-04-28
NZ731946A (en)	2021-02-26
DK3461821T3 (da)	2020-08-17
PL3461821T3 (pl)	2020-10-19
KR102030305B1 (ko)	2019-10-08
TWI744218B (zh)	2021-11-01
US10329274B2 (en)	2019-06-25
SG10201903578VA (en)	2019-05-30
JP6517928B2 (ja)	2019-05-22
IL251797A0 (en)	2017-06-29
ES2809974T3 (es)	2021-03-08
KR20170061175A (ko)	2017-06-02
EA201790740A1 (ru)	2017-08-31
EP3209656A1 (en)	2017-08-30
IL262206B (en)	2020-07-30
US20230192645A1 (en)	2023-06-22
ES2795366T3 (es)	2020-11-23
EA032277B1 (ru)	2019-05-31
MA40301B1 (fr)	2019-12-31
ZA201804893B (en)	2020-07-29
US11623921B2 (en)	2023-04-11
SI3209656T1 (sl)	2020-07-31
PE20190710A1 (es)	2019-05-17
CN110511209B (zh)	2022-07-05
KR20180132167A (ko)	2018-12-11
US20200165222A1 (en)	2020-05-28
TN2018000218A1 (en)	2019-10-04
SG11201703188QA (en)	2017-05-30
NZ754113A (en)	2021-02-26
PH12017500725A1 (en)	2017-10-09
PH12017500725B1 (en)	2017-10-09
CY1123401T1 (el)	2021-12-31
MY188048A (en)	2021-11-12
EP3209656B1 (en)	2020-04-01
CN107108583A (zh)	2017-08-29
PH12020500265A1 (en)	2021-02-22
PT3461821T (pt)	2020-08-05
ME03807B (me)	2021-04-20
IL262206A (en)	2018-11-29
RS60312B1 (sr)	2020-07-31

Publication	Publication Date	Title
ME03740B (me)	2021-01-20	Jedinjenja indol karboksamida korisna kao inhibitori kinaze
HUS2400003I1 (hu)	2024-03-28	Kináz inhibitorként alkalmas vegyületek
HK1231411A1 (zh)	2017-12-22	作為抑制劑的取代的吲唑化合物
HK1231480A1 (zh)	2017-12-22	作為抑制劑的吲唑化合物
ZA201700115B (en)	2020-05-27	Aminopyridazinone compounds as protein kinase inhibitors
IL246785A0 (en)	2016-08-31	Benzimidazole-2-amines as midh1 inhibitors
HK1226398A1 (zh)	2017-09-29	作為midh1抑制劑的苯並咪唑-2-胺
HK1232215A1 (zh)	2018-01-05	作為醛固酮合酶抑制劑的新型二氫喹啉吡唑基化合物
GB201522245D0 (en)	2016-02-03	Compounds useful as kinase inhibitors
GB201409661D0 (en)	2014-07-16	Novel compounds and their use as kinase inhibitors
GB201405532D0 (en)	2014-05-14	Novel compounds and their use as Kinase inhibitors